Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th
Abroad (travel likely)RecruitingPHASE3
Conditions
Autism Spectrum Disorders
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Assistance Publique Hopitaux De Paris, Paris, France
Contact: Principal Investigator (Richard Delorme, PhD)Hospital Clinic De Barcelona, Barcelona, Spain
Contact: Principal Investigator (Rosa Calvo, PhD)Hospital General Universitario Gregorio Marañón, Madrid, Spain
Contact: Principal Investigator (María José Parellada, PhD)Hospital Universitario De Salamanca, Salamanca, Spain
Contact: Principal Investigator (Ricardo Canal-Bedia, PhD)Complejo Asistencial De Zamora Hospital Provincial De Zamora, Zamora, Spain
Contact: Study coordinator (Manuel Angel Franco, PhD) · mfrancom@saludcastillayleon.es · +34669462622Contact: Principal Investigator (Manuel Angel Franco, PhD)